SeQuent Scientific Announces Acquisition Of Bremer Pharma In Germany
SeQuent Scientific Limited (SeQuent), announced that its wholly-owned subsidiary Alivira Animal Health Limited (Alivira) through Alivira Ireland, has signed an agreement with simultaneous closing to acquire 100% of Bremer Pharma, Zydus Cadila’s Animal Health Business in Germany.
Bremer Pharma, founded in 1982 is a niche veterinary health company in Germany with focus on cattle and swine segments. Bremer has a portfolio of over 400+ registered products across Europe, Far East, MENA, Russia & Africa operating in vitamins, antibiotics and hormones. Bremer registered sales of €6.7Mn ($8.3Mn) in year ending March 31, 2018, with marginal losses. Bremer comes with a EUGMP compliant injectable manufacturing facility with approval from German Competent Authority LANUV. The site was recently reinspected and obtained a renewed GMP certificate on 12th March 2018.
This acquisition provides Alivira’s with a beta-lactam & non-beta lactam injectables facility for EU markets, which compliments its orals & powders beta-lactam and non-beta lactam facility based at Barcelona in Spain. EU is Alivira’s largest market accounting to 60% of revenues.
With this acquisition, Alivira is a ~$150 Mn business on an annualized basis with the presence in 95+ countries. Alivira has a strong presence in the formulations business in key veterinary markets of Europe, LATAM, India, Turkey, Africa and South East Asian countries. Over 80% of the revenues of Alivira are generated outside India, with manufacturing operations in Spain, Germany, Brazil, India and Turkey and R&D development in India, Turkey and Spain.
In last 36 months Alivira has successfully acquired and integrated over 8 businesses globally. These successful integrations, coupled with the commercialization of API’s in US and aggressive new product development program will create sustainable value and speed up the revenue and margin growths in the coming years.